Table 5 National-level budget impact analysis (in EUR)
2-year follow-up | ||||||
|---|---|---|---|---|---|---|
Lens structure (hydrophobic/hydrophilic) | 0%/100% | 20%/80% | 40%/60% | 60%/40% | 80%/20% | 100%/0% |
Expected rate of complications | 22.00% | 18.58% | 15.16% | 11.74% | 8.32% | 4.90% |
Cataract surgery | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 | 1,35,746, 844 | 1,35,746,844 |
Nd:YAG | 4,495,683 | 3,796,808 | 3,097,934 | 2,399,060 | 1,700,185 | 1,001,311 |
Consultation | 6,42,240 | 5,42,401 | 4,42,562 | 3,42,723 | 2,42,884 | 1,43,044 |
Diclofenac | 2,78,893 | 2,35,538 | 1,92,183 | 1,48,827 | 1,05,472 | 62,117 |
Total | 1,41,163,660 | 1,40,321,592 | 1,39,479,523 | 1,38,637,454 | 1,37,795,386 | 1,36,953,317 |
3-year follow-up | ||||||
Lens structure (hydrophobic/hydrophilic) | 0%/100% | 20%/80% | 40%/60% | 60%/40% | 80%/20% | 100%/0% |
Expected rate of complications | 30.0% | 26.80% | 23.60% | 20.40% | 17.20% | 14.00% |
Cataract surgery | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 | 1,35,746,844 |
Nd:YAG | 6,130,476 | 5,476,559 | 4,822,641 | 4,168,724 | 3,514,806 | 2,860,889 |
Consultation | 8,75,782 | 7,82,366 | 6,88,949 | 5,95,532 | 5,02,115 | 4,08,698 |
Diclofenac | 3,80,308 | 3,39,742 | 2,99,176 | 2,58,610 | 2,18,044 | 1,77,477 |
Total | 1,43, 133,411 | 1,42,345,511 | 1,41,557,610 | 1,40, 769,710 | 1,39, 981,809 | 1,39,193,909 |